Sanofi (SNY)'s Sarclisa Gets EMA Nod for Multiple Myeloma

We recently published 11 Best Cancer Stocks to Buy Right Now. Sanofi is placed eighth among them.

Sanofi (NASDAQ:SNY) is a global biopharmaceutical company focused on innovative medicines and vaccines, with active efforts in oncology, immunology, and rare diseases. The company is recognized for its scientific approach and robust pipeline development.

In oncology, a key recent development is the European Medicines Agency’s acceptance of Sanofi (NASDAQ:SNY) ’s Sarclisa (isatuximab) for regulatory review in combination therapies for transplant-eligible, newly diagnosed multiple myeloma (NDMM). The supporting Phase 3 GMMG-HD7 study demonstrated a 30% reduction in disease progression or death, highlighting Sarclisa’s potential impact on multiple myeloma treatment.

The company’s late-stage pipeline includes 12 potential blockbuster cancer therapies, with some projected to exceed €5 billion in peak sales. The corporation employs an “immunience” approach, leveraging immune pathway research to advance cancer immunotherapy and broader immunological applications. Ongoing Phase 3 programs and innovative treatments across rare diseases and immunology further reflect Sanofi’s comprehensive R&D investment.

Beyond drug development, the business’s philanthropic arm, Foundation S, focuses on reducing childhood cancer and supporting WHO initiatives to cut childhood cancer rates by 60%, while addressing health equity and access issues.

While we acknowledge the potential of SNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.